PA
TKC icon

PharVision Advisers’s Turkcell TKC Stock Holding History

PharVision Advisers’s Portfolio TKC Stock Details TKC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.5K Sell
12,671
-6,112
-33% -$37.5K 1.4% 37
2026
Q1 		$113K Buy
18,783
+299
+2% +$1.9K 1.15% 38
2025
Q4 		$101K Buy
+18,484
New +$108K 0.05% 654

Other funds holding TKC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

PharVision Advisers's TKC Position: Q2 2026 in Review

PharVision Advisers reduced its Turkcell (TKC) stake by 33% in Q2 2026, selling an estimated $37.5K and leaving 12,671 shares worth $74.5K. The position accounts for 1.4% of the portfolio, ranked #37.

PharVision Advisers first reported a position in TKC in Q4 2025 and has held it in 3 quarters since. The position peaked at $113K in Q1 2026. 174 funds tracked by Wall St. Rank hold TKC as of Q2 2026.

  • PharVision Advisers held 12,671 shares of Turkcell worth $74.5K as of Q2 2026.
  • PharVision Advisers sold 6,112 Turkcell shares in Q2 2026, an estimated $37.5K.
  • Turkcell made up 1.4% of PharVision Advisers's portfolio in Q2 2026, its #37 holding.
  • PharVision Advisers first reported a position in Turkcell in Q4 2025 and has held it in 3 quarters since.
  • PharVision Advisers's Turkcell position peaked at $113K in Q1 2026.
  • 174 funds tracked by Wall St. Rank held Turkcell as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.